ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 107,40
-0,42%
Dow Jones
39 872,99
0,17%
DAX
18 687,48
-0,21%
Brent Oil
81,685
-0,92%
Bitcoin
69 736,92
-0,56%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Esperion Therapeutics Inc (ESPR)

  7. Esperion Therapeutics Inc (ESPR) Actualités

ESPR

Esperion Therapeutics (ESPR)

Esperion Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ESPR
DateHeureSourceTitreSymboleSociété
20/05/202422h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
20/05/202412h00GlobeNewswire Inc.Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for HypercholesterolemiaNASDAQ:ESPREsperion Therapeutics Inc
17/05/202421h08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
14/05/202414h00GlobeNewswire Inc.Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®NASDAQ:ESPREsperion Therapeutics Inc
10/05/202422h00GlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
08/05/202422h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
07/05/202414h50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ESPREsperion Therapeutics Inc
07/05/202412h00GlobeNewswire Inc.Esperion Reports First Quarter 2024 Financial ResultsNASDAQ:ESPREsperion Therapeutics Inc
29/04/202414h00GlobeNewswire Inc.Esperion to Participate in Upcoming May Investor ConferencesNASDAQ:ESPREsperion Therapeutics Inc
23/04/202414h00GlobeNewswire Inc.Esperion to Report First Quarter 2024 Financial Results on May 7NASDAQ:ESPREsperion Therapeutics Inc
07/04/202420h45GlobeNewswire Inc.Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with ObesityNASDAQ:ESPREsperion Therapeutics Inc
01/04/202414h00GlobeNewswire Inc.Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024NASDAQ:ESPREsperion Therapeutics Inc
26/03/202413h00GlobeNewswire Inc.Esperion to Participate in 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ESPREsperion Therapeutics Inc
25/03/202421h00GlobeNewswire Inc.Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24NASDAQ:ESPREsperion Therapeutics Inc
22/03/202423h26Business WireU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseNASDAQ:ESPREsperion Therapeutics Inc
22/03/202420h10GlobeNewswire Inc.U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseNASDAQ:ESPREsperion Therapeutics Inc
22/03/202416h04GlobeNewswire Inc.CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular EventsNASDAQ:ESPREsperion Therapeutics Inc
27/02/202415h19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ESPREsperion Therapeutics Inc
27/02/202412h00GlobeNewswire Inc.Esperion Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ESPREsperion Therapeutics Inc
14/02/202420h14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
13/02/202414h00GlobeNewswire Inc.Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27NASDAQ:ESPREsperion Therapeutics Inc
01/02/202420h00GlobeNewswire Inc.RFK, Esperion Therapeutics Announce 2024 Promotional ScheduleNASDAQ:ESPREsperion Therapeutics Inc
23/01/202422h00GlobeNewswire Inc.Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional SharesNASDAQ:ESPREsperion Therapeutics Inc
22/01/202412h04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ESPREsperion Therapeutics Inc
19/01/202403h15GlobeNewswire Inc.Esperion Announces Pricing of $85.1 Million Public Offering of Common StockNASDAQ:ESPREsperion Therapeutics Inc
18/01/202422h00GlobeNewswire Inc.Esperion Announces Proposed Public Offering of Common StockNASDAQ:ESPREsperion Therapeutics Inc
03/01/202421h15Business WireEsperion e Daiichi Sankyo Europe annunciano un emendamento da 125 milioni di dollari alla loro collaborazione, compresa la risoluzione di una controversia in corsoNASDAQ:ESPREsperion Therapeutics Inc
03/01/202419h54Business WireEsperion et Daiichi Sankyo Europe annoncent une révision de leur collaboration pour un montant s’élevant à 125 millions USD, assortie de la résolution d’un litige en coursNASDAQ:ESPREsperion Therapeutics Inc
03/01/202416h07Business WireEsperion und Daiichi Sankyo Europe geben Anpassung ihrer Zusammenarbeit in Höhe von 125 Millionen US-Dollar sowie die Beilegung eines anhängigen Rechtsstreits bekanntNASDAQ:ESPREsperion Therapeutics Inc
03/01/202413h00GlobeNewswire Inc.Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending LitigationNASDAQ:ESPREsperion Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ESPR

Dernières Valeurs Consultées

BIT
P1SXJ6
BNP Paribas Issuance
COIN
MUUUST
Miracle Universe
BIT
F17426
Vontobel Financial Produ...
BIT
S29244
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés